However, for patients with advanced or metastatic BLCA, EPHB6-directed therapy could potentially serve as a stimulator to immune checkpoint inhibitors (ICIs), reprogramming a cold immune tumor microenvironment into a hot one, which merited further study and investigation. This evidence concerns the gene EPHB6 and bladder transitional cell carcinoma.